AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05406999
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg (40 mg× 4 tablets) once daily, orally.
Trial: NCT05406999
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 240 mg (60 mg×4 tablets) once daily, orally.
Trial: NCT05406999
Drug: Darotamide
RxNorm normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg (300 mg × 2 tablets) twice daily, orally.
Trial: NCT05406999
Drug: Rezvilutamide
RxNorm normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg (80 mg × 3 tablets) once daily orally
Trial: NCT05406999
Drug: PARP inhibitor
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
Trial: NCT00884000
Drug: Genotropin
RxNorm normalized name: Genotropin
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00884000
Drug: Zomacton
RxNorm normalized name: Zomacton
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01166763
Drug: vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules, 10,000 IU per week for 6 months
Trial: NCT01528254
Drug: Placebo of vildagliptin
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01528254
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
Trial: NCT01528254
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Trial: NCT01822405
Drug: pentoxifylline with tocopherol
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
Trial: NCT03569007
Drug: Larazotide
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
Trial: NCT00271570
Drug: Infliximab (Remicade)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remicade was 5 mg/kg IV (single dose)
Trial: NCT04034173
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 6 mg/kg BW as 60-min i.v. infusion\* D1~\*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes.
Trial: NCT04034173
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
Trial: NCT04034173
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
Trial: NCT01081938
Drug: INSULIN GLARGINE
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine
Trial: NCT01081938
Drug: INSULIN GLULISINE
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine
Trial: NCT00482456
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04034173
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
Trial: NCT00438087
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methylprednisolone administrated intra and post operatively
Trial: NCT04385836
Drug: alpha one antitrypsin inhalation
RxNorm normalized name: alpha 1-antitrypsin
DrugBank: Trypsin (DB11237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - we will give 8 ml of intravenous alpha one antitrypsin (alpha1-proteinase inhibitor (AATD)Glassia 50 ml) as nebulizer every 12 hours for 5 days
Trial: NCT02786511
Drug: Safety and efficacy assessments
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
Trial: NCT02172742
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
Trial: NCT04455802
Drug: Buprenorphine or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The double blind, double dummy design necessitates that both drugs be on an identical schedule. The 4-hour dosing allows for this pairing. If a patient is randomized to the buprenorphine arm, medication administration will follow an every 8-hour dosing but medication will be substituted with placebo during the intermediary time point.
Trial: NCT04455802
Drug: Morphine or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If a patient is randomized to the morphine arm, morphine will be given every 4 hours. Placebo will also be given at the same frequency as a faux drug.
Trial: NCT04918264
Drug: Fluoropyrimidine treatment (5-FU or capecitabine) and dosage
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each group with an uracil dosage; at cycle 1; capecitabine or continuous 5-FU dose percentage will be evaluate retrospectively in our database
Trial: NCT00005898
Drug: anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005898
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005898
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00005898
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005898
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03622931
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02563353
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide, 20 microgram/day. 24 months of treatment.
Trial: NCT00225758
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1500 mg po daily for 26 weeks or longer
Trial: NCT01524692
Drug: Dovitinib (TKI258)
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
Trial: NCT03403595
Drug: 177Lu-EB-PSMA-617
RxNorm normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
Trial: NCT01721330
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up to 100mg of Naltrexone once a day for 6 weeks
Trial: NCT02883153
Drug: Zirconium-89 girentuximab PET/CT
DrugBank: Girentuximab (DB05304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
Trial: NCT02235012
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
Trial: NCT02049944
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
Trial: NCT02106559
Drug: porfimer sodium
RxNorm normalized name: Porfimer Sodium
DrugBank: Porfimer sodium (DB00707)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00004941
Drug: monoclonal antibody cA2
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02453191
Drug: Talimogene Laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene Laherparepvec
Trial: NCT02636322
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02636322
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02636322
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02636322
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02636322
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00513864
Drug: Dextromethorphan
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one time dose - 0.3mg/kg PO
Trial: NCT00513864
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one time dose - 0.15mg/kg IV
Trial: NCT02502071
Drug: sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive 2 doses of 1950mg sodium bicarbonate
Trial: NCT02696577
Drug: Low dose aspirin
RxNorm normalized name: Adult Low Dose Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02696577
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00158470
Drug: efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00158470
Drug: didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00158470
Drug: lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001082
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 120 mg tablet taken orally daily
Trial: NCT00001082
Drug: Adefovir dipivoxil placebo
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral placebo tablet taken daily
Trial: NCT03969758
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
Trial: NCT03969758
Drug: Cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
Trial: NCT02618187
Drug: SER-287
RxNorm normalized name: SER-287
DrugBank: SER-287 (DB18204)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02618187
Drug: Vancomycin Pre-Treat
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02229292
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure.
Trial: NCT02229292
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure.
Trial: NCT00052715
Drug: poly ICLC
RxNorm normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01936974
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient to receive gemzar
Trial: NCT01936974
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient to receive avastin
Trial: NCT01936974
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient to receive carboplatin
Trial: NCT01936974
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient to receive cisplatin
Trial: NCT01936974
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient to receive Oxaliplatin
Trial: NCT00986583
Drug: Succinylcholine
RxNorm normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine will be administered pre-induction over a period of 5 seconds
Trial: NCT02261532
Drug: TAS-102
RxNorm normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Trial: NCT01466231
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
Trial: NCT03335267
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytarabine:Daunorubicin Liposome Injection
Trial: NCT03673228
Drug: Nicotine Replacement Therapy (NRT)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in both arms will be encouraged to receive NRT
Trial: NCT00051142
Drug: Travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00051142
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01452789
Drug: sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
Trial: NCT01452789
Drug: oral morphine
RxNorm normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
Trial: NCT01982227
Drug: indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
Trial: NCT02285244
Drug: sotrastaurin acetate
RxNorm normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00500929
Drug: CMI X-11S
RxNorm normalized name: Cmi x-11s
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02492776
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg oral capsules administered once daily for 8 days
Trial: NCT02492776
Drug: Gefapixant
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
Trial: NCT02492776
Drug: Gefapixant
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
Trial: NCT00369863
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01297114
Drug: Florbetaben
RxNorm normalized name: florbetaben
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
Trial: NCT03366415
Drug: gemcitabine and cisplatin (Induction and adjuvant chemotherapy)
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before IMRT and after IMRT.
Trial: NCT03366415
Drug: gemcitabine and cisplatin (Induction chemotherapy)
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before concurrent chemoradiotherapy.
Trial: NCT03055507
Drug: OxyCODONE 5 Mg Oral Tablet
RxNorm normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard PRN medication offered post-operatively for breakthrough pain
Trial: NCT01578720
Drug: EYLEA (Aflibercept) intravitreal injection
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal Injection once every 8 weeks with 3 initial monthly doses
Trial: NCT02315196
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV